25-28 SEP 2024


25-28 SEPTEMBER 2024


Call for abstracts

Submit your abstract and contribute to shaping the future of dermatology and venereology during the 2024 EADV Congress in Amsterdam.

Don’t miss the opportunity to showcase your research directly to a worldwide audience, enhancing your visibility among influential thought leaders and industry experts. Selected authors will have the chance to present their work in the oral Free Communication sessions.


Abstract submission deadline

24 Apr 2024

8 May 2024


Abstract outcome 18 July 2024

Late breaking abstracts submission deadline

  • Opens 13 Aug 2024
  • Closes 26 Aug 2024

We invite authors to specify if they prefer their submission to be considered for:

  • e-Poster presentation only
  • Oral presentation only
  • Indifferent

If you submit your abstract as “Oral presentation” and it does not get selected for one of the Free Communication sessions, you will still have the possibility to present it as e-poster (if the abstract is deemed acceptable).

  • Abstracts must be submitted in English. A “blind” selection process will be used.
  • No identifying features such as names of hospitals, medical schools, clinics or cities may be listed in the title or text of the abstract. Do not include the names of authors either. Their names and affiliations (institutions) will be registered separately when submitting the abstract online.
  • The title should not be written entirely in capital letters.
  • The size of the abstract is limited to 3,000 characters.
  • The submission program will automatically calculate the size of your abstract and will not allow submissions that do not fit in the size requirements.
  • Tables and figures (graphs) are allowed and they are not taken into consideration for the character count. On the other hand, pictures of patients and body parts are NOT allowed. Abstract containing pictures will be rejected.
  • In order to be able to submit your abstract you must use the template downloadable on the submission platform.
  • Check spelling and grammar carefully. Direct reproduction from your electronically submitted abstract text means that any errors in spelling, grammar or scientific data will be reproduced as submitted.
  • Use generic names. The use of commercial drug names, brands and registered trademarks are strictly prohibited. Drugs should be referred to by the active substance or pharmacological designation.
  • No mention of pharmaceutical company names should be included in the abstract.

The evaluation and scoring of the abstract (acceptance as poster or as oral communication, or rejection) will be made according to a number of criteria, including:

  • Is the content interesting, informative, novel or important?
  • Are the methods valid, the results relevant and the conclusions justified by the data?
  • Is the data presented with clarity and with appropriate structure?
  • Is the text written according to proper English grammar and syntactic style?

Submission of an abstract implies that it has been approved by all listed authors.

The Scientific Programming Committee reserves the right to make the final decision concerning the form of presentation.

As part of the submission, the author grants EADV the exclusive right to first publish the abstract, and thereafter a non-exclusive right to publish, reproduce, distribute, display and store the abstract worldwide in all forms (including on the EADV website), formats and media now known or as developed in the future, including print, electronic and digital forms. For the avoidance of doubt, “electronic and digital forms” shall include but shall not be limited to databases, USB and forms accessible via electronic and digital networks, wireless transmission and communication systems. The author also grants EADV the exclusive right to retain income resulting from the above-mentioned publications by EADV. No fee shall be paid to the author by EADV for the license granted herein. The author will retain copyright of his or her abstract, including the pertaining moral rights. However, the author shall only reuse, reproduce or post the abstract with acknowledgment to the initial and first publication or presentation at an EADV event, and therefore reference the name of the EADV event and the date.

The License of Copyright Use between EADV and the author is governed and construed in accordance with the laws of Switzerland.

Accepted abstracts will be published on our official website.

Every abstract author and meeting attendee, whether from the media, companies, institutions, organisations, universities, investment advisors, or any other category, must adhere to the embargo policy.

Embargoed materials include – but are not limited to – abstracts submitted to the EADV Events, abstracts from scientific meetings, original journal articles, written news releases, audio news releases, video news releases, interviews, slides, and any other materials associated with the scientific information being presented or published.

Embargoed materials, as well as results and information related to sessions at any meeting or event organised by EADV, are strictly confidential and cannot be disclosed in any manner or for any purpose before the lifting of the embargo by EADV.

Breaking an EADV embargo by any author, media outlet, press representative, member of staff or any third party acting on behalf of and/or under the authority of any media outlet or press representative is a contractual breach. The person/entity who released the information (i.e. the press representative who wrote the story/conducted the interview, etc.) will be held accountable and subjected to penalties.

Prior publication

If the abstract is also submitted as a manuscript for publication, authors are responsible for coordinating a publication date that abides by the embargo policy. If publication occurs online or in print before the specific embargo date and time set by the EADV, the abstract must be withdrawn or presented as an encore. Please notify the EADV via email at

Embargo Date and Time

All abstracts:

The embargo is lifted at 7:00 CEST on 25 September 2024. Abstracts will be published on the EADV Event platform and accessible to registered participants.

Industry abstracts:

The embargo is lifted at 7:00 CEST on 25 September 2024. Abstracts will be published on the EADV Event platform and accessible to registered participants.

Before this date, only top-line content (no results or data) can be disclosed to announce the session content, learning outcomes and speakers.


There are no costs for abstract submission.

The submitter does not need to be registered to the event

The submitter does not have to be an author of the abstract being submitted.

Yes. There is no limit to the number of abstracts that one can submit.

The submitter, and email address used by the submitter, will receive the notification.

It is not necessary for the presenting author to be the first author. Anyone from the authors list can present the abstract.

Yes, the presenting author act as a presenter for multiple abstracts

There is no limit to the number of authors on an abstract.

There are no word or character limits for the abstract title.

Yes, encores and/or adaptations are permitted.

Yes, QR codes are permitted on posters.

The content of the abstracts accepted as e-posters will be under embargo until the first day of the EADV event. Content of abstracts accepted as oral presentations will be under embargo until the date and time of the presentation of the abstract.

This does not apply to encores.

Abstracts can be withdrawn until 4 weeks before the event, on Thursday 28 August 2024.

If you have any further questions about the Scientific Programme, Abstracts, CME Accreditation, or Certificates, please contact us at


Important note to Healthcare and Non-Healthcare Professionals

Access to the different areas and sessions of the Congress depends on the status. Please read the description below to ensure you/your delegates comply with the regulations in place.
EADV Members are not designated as Healthcare Professionals by default. Please attribute the correct status (HCP or Non-HCP) during registration.


A multidisciplinary audience will attend the EADV Congress, and the EADV will assign different classes to healthcare professionals (HCP) and non-Healthcare Professionals (non-HCP) to ensure compliance with these regulations.

Chapter 3 of the Dutch CGR code defines HCPs as follows:
3.1 In the purpose of this Code of Conduct, the following terms shall bear the following meaning:
healthcare professionals: persons qualified to prescribe or supply prescription-only medicinal products.

Further explanation is provided in The General information about organising scientific meetings and Frequently Asked Questions from the CGR (Dutch Foundation for the Code for Pharmaceutical Advertising (to be referred to as the general information document from here on out) (20170214 CGR informatie congresorganisaties), where it states (at section 2 a, page 2) that: In the Netherlands the group of healthcare professionals comprises: physicians, physicians who are being trained to become a specialist (‘artsen in opleiding’), pharmacists, pharmacist’s assistants, obstetricians, dentists, physician assistants, nurse practitioners and specialised nurses.

Dutch Nurses, in Particular

It further clarifies that:
… “Specialised nurses (limited to the lung, diabetes and oncology areas) only have independent prescription authority if they have completed a specific training programme for this purpose. The completion of this training is entered in the BIG register and so can be checked by anyone. This means that all of the other healthcare providers, such as regular nurses, dieticians, dental hygienists or supportive GP practitioners (‘praktijkondersteuners’), are not healthcare professionals and so – just like patients – belong to the ‘general public’. This group will be referred to below as ‘non-healthcare professionals’.
In terms of specialised nurses, the explanatory notes to the CGR code (20200701 Explanatory Notes CGR per 20200701) provide a specific list to be taken into consideration:

“3.1.d Definition of “healthcare professional”
…. pharmacist’s assistants and nurses with the additional BIG registrations:
Specialised nurses (gespecialiseerd verpleegkundigen):

  • Diabetes nurses
  • Pulmonary care nurses
  • Oncology nurses

Specialised nurses may only be considered as healthcare professionals if their BIG registration states that they have prescription authority. ….
Nurse specialists (NS) (verpleegkundig specialisten):

  • NS providing general healthcare
  • NS providing mental healthcare


Lastly, the explanatory notes state (at page 3) that:
Physicians in training to become a specialist (artsen in opleiding) are also considered as healthcare professionals within the meaning of the Code of Conduct. Medical students are not considered healthcare professional (see Newsletter 2006/4).

Other Categories

The general information document (sections 2d and e, page 3) goes on to clarify that industry employees and specialised journalists can be exposed to promotional content. Yet patients, patient representatives, and regular press or specialised journalists who target the general public will still be considered non-HCPs and should not be exposed to promotional content.
STUDENTS are NOT considered as Healthcare Professionals under the current
guidelines and will be automatically classified as NON-HEALTHCARE PROFESSIONALS.

Industry sessions

Satellite Symposia and Industry Hub Sessions presenting data on the development, research, or other issues related to prescription medicine is restricted to Healthcare Professionals and Industry Participants as indicated by the Industry Session Organizer. All promotional materials and marketing aids related to these industry sessions should be strictly limited to HCPs. Industry Session organisers can limit participation to certain representative groups independently from the EADV recommendations if deemed imperative to achieving the session’s intended purpose. The organising company reserves the right to refuse single categories, particularly if they are not adequately related to the session’s objective and purpose.

The industry session organiser is responsible for compliance with the session.